| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.032 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.029 | 0.9 |